deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05185947

Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Appendiceal Cancer Appendiceal Neoplasms Colorectal Cancer Colorectal Neoplasms Gynecologic Cancer Gynecologic Neoplasms Ovarian Cancer Ovarian Neoplasms Peritoneal Carcinomatosis Peritoneal Neoplasms
Interventions Nilotinib Paclitaxel
Updated 33 times since 2022 Last updated: Mar 6, 2025 Started: Oct 13, 2022 Primary completion: Jan 27, 2025 Completion: Apr 4, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Appendiceal Cancer and Appendiceal Neoplasms and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 33 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Nov 2022 · 31 days · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Apr 2024 · 2 months · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Apr 2025 · 59 days · monthly snapshot~Apr 2025 – present · 15 months · monthly snapshot

Change History

33 versions recorded

  1. Apr 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Feb 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2025 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Dec 2024 — Jan 2025 [monthly]

    Recruiting PHASE2

  5. Nov 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

▶ Show 28 earlier versions

  1. Oct 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  2. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  3. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

  5. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  6. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE2

  7. Apr 2024 — May 2024 [monthly]

    Recruiting PHASE2

  8. Feb 2024 — Apr 2024 [monthly]

    Recruiting PHASE2

  9. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE2

  10. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  11. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  12. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  13. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  14. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  15. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  16. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  17. Apr 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  18. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  19. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  20. Nov 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  21. Oct 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  22. Sep 2022 — Oct 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  23. Jul 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE2

  24. Jun 2022 — Jul 2022 [monthly]

    Not Yet Recruiting PHASE2

  25. May 2022 — Jun 2022 [monthly]

    Not Yet Recruiting PHASE2

  26. Apr 2022 — May 2022 [monthly]

    Not Yet Recruiting PHASE2

  27. Mar 2022 — Apr 2022 [monthly]

    Not Yet Recruiting PHASE2

  28. Feb 2022 — Mar 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations